GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced it will release financial results for the first quarter of 2026 after...
Program to expand access to exome sequencing to help clinicians confirm diagnosis and guide clinical decision-making in NPC
GeneDx showcases leadership in exome and genome quality, expanded access through non-genetics ordering, and AI-driven innovations that enhance speed, scale, and diagnostic impact
Shareholders should contact the firm immediately as there may be limited time to enforce your rights.
GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced that company management will participate in upcoming investor conferences:...
Reported fourth quarter 2025 revenues of $121.0 million with 32% year-over-year growth in exome and genome test revenue (42% excluding a one-time 2024 benefit) ...
Recognition highlights growing global impact of rare disease diagnosis and the role of genomics in transforming health outcomes
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced it will release financial results for the fourth quarter of 2025 before the market opens...
Shareholders should contact the firm immediately as there may be limited time to enforce your rights.